Genome & Company (KOSDAQ:314130)

-30.01% (1Y)

Market Cap	90.61B
Revenue (ttm)	29.84B
Net Income (ttm)	-19.04B
Shares Out	31.09M
EPS (ttm)	-619.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	167,430
Average Volume	295,525
Open	3,015.00
Previous Close	2,985.00
Day's Range	2,900.00 - 3,035.00
52-Week Range	2,170.00 - 5,870.00
Beta	1.28
RSI	53.23
Earnings Date	Aug 14, 2025

About Genome & Company

Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors, as well as microbiome-based products, including therapeutics, co...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 98
• Stock Exchange: KOSDAQ
• Ticker Symbol: 314130

Financial Performance

In 2024, Genome & Company's revenue was 27.74 billion, an increase of 94.07% compared to the previous year's 14.30 billion. Losses were -20.11 billion, -57.63% less than in 2023.